Please try another search
For the three months ended 31 March 2022, InnoTherapy Inc revenues decreased 53% to W73M. Net loss increased 38% to W1.6B. Revenues reflect Hemostatic segment decrease of 49% to W73M, Service segment decrease from W13.6M to W0K, South Korea (Country) segment decrease of 68% to W39.8M. Higher net loss reflects Loss under Equity Method increase of 68% to W146.5M (expense), Depreciation in R&D increase from W12.4M to W71.3M (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 633.02 | 287.3 | 215.62 | 186.16 |
Gross Profit | 56.16 | 108.46 | 5.38 | 38.41 |
Operating Income | -846.37 | -958.57 | -1135.07 | -1077.18 |
Net Income | -705.56 | 477.87 | -3585.17 | -1213.42 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 30157.9 | 23323.08 | 30168.37 | 34119.87 |
Total Liabilities | 11255.03 | 9861.16 | 15716.57 | 16433.08 |
Total Equity | 18902.87 | 13461.92 | 14451.8 | 17686.79 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -161.73 | -514.04 | -829.18 | -1314.48 |
Cash From Investing Activities | -4944.61 | 2819.93 | 3107.11 | 549.95 |
Cash From Financing Activities | 6663.91 | -5825.23 | -418.11 | 4089.63 |
Net Change in Cash | 1555.21 | -3517.2 | 1924.59 | 3261.36 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review